Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome;Concentraciones plasmáticas de renina y aldosterona en mujeres obesas y no obesas con síndrome de ovarios poliquísticos

Endocrinologia y Nutricion

Volumn 59, Issue 1, 2012, Pages 21-27

  Mejia Montilla, Jorly ^a   Reyna Villasmil, Eduardo ^a   Torres Cepeda, Duly ^a   Santos Bolívar, Joel ^a   Reyna Villasmil, Nadia ^a   Bravo Henríquez, Alfonso ^b  

^a HOSPITAL CENTRAL DR URQUINAONA   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Aldosterone; Plasma renin activity; Polycystic ovary syndrome; Renin

Indexed keywords

ALDOSTERONE; ANDROSTENEDIONE; FOLLITROPIN; LUTEINIZING HORMONE; RENIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ALDOSTERONE BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT SELECTION; PLASMA RENIN ACTIVITY; TESTOSTERONE BLOOD LEVEL;

ADULT; ALDOSTERONE; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; INSULIN; LUTEINIZING HORMONE; MODELS, BIOLOGICAL; OBESITY; POLYCYSTIC OVARY SYNDROME; RENIN; SEX HORMONE-BINDING GLOBULIN; WAIST-HIP RATIO; YOUNG ADULT;

EID: 84856223704     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.09.003     Document Type: Article

References (29)

1. Hassa H., Tanir H., Yildiz Z. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. Arch Gynecol Obstet 2006, 274:227-232.
2. Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest 2010, 69:274-280.
3. Hahn S., Tan S., Sack S., Kimmig R., Quadbeck B., Mann K., et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2007, 115:130-135.
4. Dunaif A., Segal K., Shelley D., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41:1257-1266.
5. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R., Yu L., et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
6. Huang Y., Noble N., Zhang J., Xu C., Border W. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007, 72:45-52.
7. Feldt S., Batenburg W., Mazak I., Maschke U., Wellner M., Kvakan H., et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008, 51:682-688.
8. Alderman M., Ooi W., Cohen H., Madhavan S., Sealey J., Laragh J. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997, 10:1-8.
9. Weber M., Giles T. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. Rev Cardiovasc Med 2006, 7:45-54.
10. Shafiq M., Miller A. Blocking aldosterone in heart failure. Ther Adv Cardiovasc Dis 2009, 3:379-385.
11. Fuller P. Aldosterone and DNA: the 50th anniversary. Trends Endocrinol Metab 2004, 15:143-146.
12. Kuster G., Kotlyar E., Rude M., Siwik D., Liao R., Colucci W., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111:420-427.
13. Hayashi T., Takai S., Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 2010, 8:189-197.
14. Matrozova J., Steichen O., Amar L., Zacharieva S., Jeunemaitre X., Plouin P. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009, 53:605-610.
15. Sealey J. Plasma renin activity and plasma prorenin assays. Clin Chem 1991, 37:1811-1819.
16. Alexiou T., Boon W., Denton D., Nicolantonio R., Walker L., McKinley M., et al. Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J Hypertens 2005, 23:945-954.
17. Colussi G., Catena C., Lapenna R., Nadalini E., Chiuch A., Sechi L. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007, 30:2349-2354.
18. Rooney D., Edgar J., Sheridan B., Atkinson A., Bell P. The effects of low dose insulin infusions on the renin angiotensin and sympathetic nervous systems in normal man. Eur J Clin Invest 1991, 21:430-435.
19. Mroczek W., Finnerty F., Catt K. Lack of association between plasma-renin and history of heart-attack or stroke in patients with essential hypertension. Lancet 1973, 2:464-468.
20. Ahokas R., Sun Y., Bhattacharya S., Gerling I., Weber K. Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells. Circulation 2005, 111:51-57.
21. Yoshii T., Iwai M., Li Z., Chen R., Ide A., Fukunaga S., et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006, 29:457-466.
22. Matsumura K., Fujii K., Oniki H., Oka M., Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006, 19:13-18.
23. Fliser D., Schaefer F., Schmid D., Veldhuis J., Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 1997, 30:1156-1161.
24. Kraus D., Jäger J., Meier B., Fasshauer M., Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005, 37:455-459.
25. Uncu G., Sözer M., Develiolu O., Cengiz C. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS. Gynecol Endocrinol 2002, 16:447-452.
26. Andreozzi F., Laratta E., Sciacqua A., Perticone F., Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004, 94:1211-1218.
27. Samy N., Hashim M., Sayed M., Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009, 26:163-170.
28. Arikan S., Akay H., Bahceci M., Tuzcu A., Gokalp D. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function. Fertil Steril 2009, 91:450-455.
29. Hacihanefioglu B., Seyisoglu H., Karsidag K., Elter K., Aksu F., Yilmaz T., et al. Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. Fertil Steril 2000, 73:261-265.